ISTA Pharma presents Prolensa Phase 3 clinical data
Meeting the study’s primary and secondary efficacy endpoints, Prolensa produced statistically greater clearing of subjects’ ocular inflammation by Day 15 and a greater proportion of subjects that were
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.